Zobrazeno 1 - 10
of 142
pro vyhledávání: ''
Autor:
Simone Grimm, Ana Lucia Herrera-Melendez, Erich Seifritz, Matti Gärtner, Malek Bajbouj, Christian Otte, Milan Scheidegger, Sabine Aust, Isabella Heuser-Collier, Anna Stippl
Publikováno v:
European Neuropsychopharmacology
Ketamine was recently approved for treatment resistant depression. However, despite its therapeutic potential, about 50% of patients do not show improvement under this therapy. In this prospective two-site study, we investigated baseline brain struct
Publikováno v:
European neuropsychopharmacology, 28(9), 1024-1034. Elsevier
Long-stay patients with severe schizophrenia are frequently treated with high doses of first-generation antipsychotics (FGA). Dose reduction or switching to ziprasidone may reduce the severity of negative symptoms and side effects. We investigated in
Autor:
Alessandro Crippa, Eleonora Maggioni, M. Pozzi, Paolo Brambilla, E. Rosi, Vaibhav A. Diwadkar, F.M. Villa, M. Molteni, M. Mauri, S. Grazioli, M. Nobile, A. Bacchetta
Publikováno v:
European Neuropsychopharmacology. 40:S34-S35
Autor:
Markus Wöhr, Luiz Kae Sales Kanazawa, Palloma de Almeida Soares Hocayen, Etieli Wendler, Rainer K.W. Schwarting, Débora Dalla Vecchia, Roberto Andreatini, Camila Pasquini de Souza
Publikováno v:
European Neuropsychopharmacology. 26:1900-1908
Drug-induced hyperlocomotion in rodents is frequently used as a behavioral model for mania. However, the use of locomotor activity as the single parameter in these animal models of mania may pose some limitations for developing new pharmacological tr
Autor:
Sylvie Bernaerts, Kaat Alaerts
Publikováno v:
European Neuropsychopharmacology. 29:S358-S359
Autor:
Haiko Sprott, Spyridon Kollias, Ulrich Schnyder, Anass Johayem, Alfred Buck, Chantal Martin-Soelch, Geoffrey Warnock, Josef Jenewein, Gregor Hasler, Katharina Ledermann
Publikováno v:
European Neuropsychopharmacology. 26:320-330
Dopamine D2/D3 receptor availability at rest and its association with individual pain perception was investigated using the [(11)C] raclopride PET-method in 24 female Fibromyalgia (FMS) participants with (FMS+, N=11) and without (FMS-, N=13) comorbid
Autor:
Luiz Felipe Souza E Silva, Ana Gutiérrez-Rodríguez, Miguel J. Martínez, Carlos Pastor Vargas, José Martínez-Orgado, María Villa, A. Del Pozo Sanz
Publikováno v:
European Neuropsychopharmacology. 31:S20
Publikováno v:
European Neuropsychopharmacology. 29:S91-S92
Autor:
Allan H. Young, Randall L. Morrison, C.T. Li, Pilar Lim, Wayne C. Drevets, Ahmad Hatim Sulaiman, Siegfried Kasper, Husseini K. Manji, David Hough, Gerard Sanacora, Ella Daly, J.W. Paik, A. Leah, Jaskaran Singh, Rosanne Lane, R. Holder, Ewa Wajs
Publikováno v:
European Neuropsychopharmacology. 29:S44-S45
Publikováno v:
European Neuropsychopharmacology. 25:295-302
The objective of this study was to evaluate the effectiveness and impact of once- versus twice-daily dosing of risperidone and olanzapine on clinical outcomes in patients with schizophrenia. Data from phase 1 of the Clinical Antipsychotic Trials of I